Physician profile
Michael C Wagner
NPI 1073655825
$11,640.17
in general payments reported to CMS, 2019-2025
48 companies · $3,273 in 2025
The $3,273 reported for 2025 was more than what 98% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,970 · 2022: $1,951 · 2023: $1,960 · 2024: $2,485 · 2025: $3,273.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,719.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,718.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,817.69 | 2021-2025 | Breztri, Airsupra, Farxiga |
| Otsuka America Pharmaceutical, INC. | $1,064.57 | 2021-2025 | Rexulti, Abilify Maintena |
| Lilly USA, LLC | $865.91 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $813.72 | 2021-2025 | Wegovy, Ozempic |
| Abbvie INC. | $793.02 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $722.09 | 2021-2025 | Verquvo, Belsomra, Steglatro |
| Glaxosmithkline, LLC. | $662.75 | 2021-2025 | Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $464.63 | 2021-2025 | Jardiance |
| Pfizer INC. | $382.58 | 2021-2024 | |
| Dexcom, INC. | $358.06 | 2021-2025 | Dexcom G7 Gss (161), Dexcom Stelo Glucose Biosensor, Dexcom G6 Transmitter |
| Amgen INC. | $324.20 | 2022-2025 | Repatha, Otezla, Otezla |
| Bayer Healthcare Pharmaceuticals INC. | $321.88 | 2022-2025 | |
| Lundbeck LLC | $222.97 | 2022-2025 | Rexulti |
| Axsome Therapeutics, INC. | $216.70 | 2023-2025 | Auvelity |
| Takeda Pharmaceuticals U.S.A., INC. | $208.02 | 2021-2025 | Trintellix |
Show all 48 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $201.67 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Janssen Pharmaceuticals, INC | $195.70 | 2021-2022 | |
| Corcept Therapeutics | $190.68 | 2023-2025 | Korlym |
| E.R. Squibb & Sons, L.L.C. | $184.48 | 2021-2025 | Eliquis |
| Xeris Pharmaceuticals, INC. | $124.59 | 2025 | Recorlev |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $123.96 | 2021-2025 | Caplyta |
| Novartis Pharmaceuticals Corporation | $115.88 | 2023-2024 | |
| Sk Life Science, INC. | $114.75 | 2022-2023 | |
| Lexicon Pharmaceuticals, INC. | $108.62 | 2023-2024 | Inpefa |
| Vanda Pharmaceuticals INC. | $101.63 | 2025 | Fanapt |
| Medtronic, INC. | $99.93 | 2021-2024 | Corevalve Evolut R, Minimed 780g |
| Electromed, INC. | $88.74 | 2021-2024 | Smartvest |
| Phathom Pharmaceuticals, INC. | $85.09 | 2024 | Voquezna |
| Insulet Corporation | $65.61 | 2022-2023 | Omnipod |
| Beta Bionics, INC. | $64.45 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Mylan Specialty L.P. | $61.24 | 2021 | |
| Clarus Therapeutics INC. | $59.14 | 2021 | |
| Abbott Laboratories | $51.88 | 2021-2022 | |
| Alkermes, INC. | $43.38 | 2022 | |
| Viatris Specialty LLC | $38.19 | 2025 | Yupelri |
| Supernus Pharmaceuticals, INC. | $35.54 | 2021-2022 | Xyosted, Tlando |
| Halozyme INC | $35.26 | 2023 | |
| Antares Pharma, INC. | $28.60 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $23.26 | 2021 | |
| Tactile Systems Technology INC | $20.66 | 2025 | Flexitouch Plus, Nimbl |
| Astellas Pharma US INC | $19.89 | 2024 | Veozah |
| Sanofi-Aventis U.S. LLC | $19.52 | 2021 | |
| Organogenesis INC. | $19.14 | 2021 | |
| Tandem Diabetes Care, INC. | $17.33 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Philips North America LLC | $16.91 | 2022 | |
| Verity Pharmaceuticals INC. | $16.27 | 2024 | Tlando |
| Watermark Medical, INC. | $15.99 | 2024 | |
| Esperion Therapeutics, INC. | $13.40 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Wagner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.